Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Table 7 Advances of RET-TKIs

Drug	Brand name	Manufacturer	Targets	Applications of diseases	Approved years or current phases of clinical trials
Selpercatinib (LOXO-292)	Retevmo	Eli Lilly and Company	RET	Metastatic RET fusion-positive NSCLC, advanced or metastatic radioactive iodine-refractory thyroid cancer, advanced or metastatic RET-mutant MTC	2020 [227, 228]
				1L advanced or metastatic RET fusion-positive NSCLC	III(NCT04194944)
				Advanced RET-mutant MTC	III(NCT04211337)
Pralsetinib (BLU-667)	–	Blueprint Medicines	RET	Advanced RET fusion-positive NSCLC	2020 [127]
				RET fusion + solid tumors	I/II [128]
				1L advanced RET fusion-positive NSCLC	III (NCT04222972)

In the last column of “Approved years or current phases of clinical trials”: both drugs were approved by Food and Drug Administration (FDA), and we also provided their current phases of clinical trials
NDA new drug application, NSCLC non-small cell lung cancer, MTC medullary thyroid cancer, RET rearranged during transfection
Data source: www.fda.gov, www.drugs.com, and www.clinicaltrials.gov (cutoff date: 19 July 2020)

ISSN: 1756-8722